Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.40 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.39 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.39 |
| ▸ | PER2 | O15055 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24726898 | 0.84 | PLA2G10 (0.39) | CHRM2CHRM1CHRM3PLA2G10PLA2G5 | |
| SCHEMBL9831208 | 0.82 | TP53 (0.45) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL8712263 | 0.82 | PLA2G10 (0.37) | CHRM2CHRM1CHRM3PLA2G10PLA2G5 | |
| SCHEMBL17951050 | 0.82 | PLA2G10 (0.42) | PLA2G10PLA2G5KDM4EALDH1A1 | |
| SCHEMBL18204610 | 0.82 | PLA2G10 (0.42) | PLA2G10PLA2G5KDM4EALDH1A1 | |
| SCHEMBL9382253 | 0.81 | PLA2G10 (0.39) | CHRM2CHRM1CHRM3PLA2G10PLA2G5 | |
| SCHEMBL8705973 | 0.81 | PLA2G10 (0.39) | CHRM2CHRM1CHRM3PLA2G10PLA2G5 | |
| SCHEMBL9383235 | 0.81 | PLA2G10 (0.39) | CHRM2CHRM1CHRM3PLA2G10PLA2G5 | |
| SCHEMBL9385983 | 0.80 | KMT2A (0.39) | PLA2G10PLA2G5 | |
| SCHEMBL9382323 | 0.80 | KMT2A (0.39) | PLA2G10PLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| US-8088794-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7858623-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312232-A1 | Substituted amide derivatives and methods of use | HGF, HGFAC, MET | CHRM2 3263/4885CHRM1 3605/4885CHRM3 3714/4885 |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | HGF, HGFAC, MET | CHRM2 3749/4885CHRM1 4091/4885CHRM3 3970/4885 |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | CHRM2 3263/4885CHRM1 3605/4885CHRM3 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.